Evidence map›Paper›PMID 31175342›Full record

ReviewNature reviews. Drug discovery2019

Bispecific antibodies: a mechanistic review of the pipeline.

Aran F Labrijn, Maarten L Janmaat, Janice M Reichert, Paul W H I Parren

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 771 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
771citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

771 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Cardiotoxicity of T cell immunotherapies.Nature reviews. Cardiology · 2026
    Review
  19. Article
  20. Article

711 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aran F LabrijnGenmab, Utrecht, Netherlands.ORCID http://orcid.org/0000-0001-9239-8439
Maarten L JanmaatGenmab, Utrecht, Netherlands.ORCID http://orcid.org/0000-0003-4980-730X
Janice M ReichertThe Antibody Society, Framingham, MA, USA.ORCID http://orcid.org/0000-0003-0400-1951
Paul W H I ParrenThe Antibody Society, Framingham, MA, USA. p.parren@lavatherapeutics.com.ORCID http://orcid.org/0000-0002-4365-3859

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from relatively small proteins, merely consisting of two linked antigen-binding fragments, to large immunoglobulin G (IgG)-like molecules with additional domains attached. An attractive bsAb feature is their potential for novel functionalities - that is, activities that do not exist in mixtures of the parental or reference antibodies. In these so-called obligate bsAbs, the physical linkage of the two binding specificities creates a dependency that can be temporal, with binding events occurring sequentially, or spatial, with binding events occurring simultaneously, such as in linking an effector to a target cell. To date, more than 20 different commercialized technology platforms are available for bsAb creation and development, 2 bsAbs are marketed and over 85 are in clinical development. Here, we review the current bsAb landscape from a mechanistic perspective, including a comprehensive overview of the pipeline.

Indexed as

Antibodies, BispecificDrug DesignNeoplasmsAnimalsBinding Sites, AntibodyClinical Trials as TopicDrug Evaluation, PreclinicalHumansMolecular Targeted TherapyAntibodies, Bispecific

Identifiers

PMID31175342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.